Terms: = Bone cancer AND CTNNB1, P35222, 1499, ENSG00000168036, CTNNB AND Treatment
26 results:
1. Class I HDAC inhibitors enhance antitumor efficacy and persistence of CAR-T cells by activation of the Wnt pathway.
Zhu M; Han Y; Gu T; Wang R; Si X; Kong D; Zhao P; Wang X; Li J; Zhai X; Yu Z; Lu H; Li J; Huang H; Qian P
Cell Rep; 2024 Apr; 43(4):114065. PubMed ID: 38578828
[TBL] [Abstract] [Full Text] [Related]
2. PDGFRβ Signaling Cooperates with β-Catenin to Modulate c-Abl and Biologic Behavior of Desmoid-Type Fibromatosis.
Hu J; Hameed MR; Agaram NP; Whiting KA; Qin LX; Villano AM; O'Connor RB; Rozenberg JM; Cohen S; Prendergast K; Kryeziu S; White RL; Posner MC; Socci ND; Gounder MM; Singer S; Crago AM
Clin Cancer Res; 2024 Jan; 30(2):450-461. PubMed ID: 37943631
[TBL] [Abstract] [Full Text] [Related]
3. [Differential diagnostic between hepatocellular carcinoma and hepatoid carcinoma with bone metastasis revelation: What tools can be used?].
Neyrand S; Bringuier PP; Benzerdjeb N; Hervieu V; Fenouil T
Ann Pathol; 2023 Sep; 43(5):407-411. PubMed ID: 36822899
[TBL] [Abstract] [Full Text] [Related]
4. Endometrioid Adenocarcinoma Resembling Cutaneous Pilomatrix Carcinoma: A Case Report of an Aggressive Neoplasm in a Young Woman With Diffusely Aberrant Beta-catenin Expression and Associated Morular Metaplasia and Atypical Polypoid Adenomyoma-type Change.
Keane E; Floyd R; McDonnell C; Beirne JP; Ó'Riain C; Komanyane L
Int J Gynecol Pathol; 2023 Sep; 42(5):466-471. PubMed ID: 36811845
[TBL] [Abstract] [Full Text] [Related]
5. RBM3 suppresses stemness remodeling of prostate cancer in bone microenvironment by modulating N6-methyladenosine on ctnnb1 mRNA.
Zhang S; Lv C; Niu Y; Li C; Li X; Shang Y; Zhang Y; Zhang Y; Zhang Y; Zeng Y
Cell Death Dis; 2023 Feb; 14(2):91. PubMed ID: 36750551
[TBL] [Abstract] [Full Text] [Related]
6. Preclinical efficacy of the Wnt/β-catenin pathway inhibitor BC2059 for the treatment of desmoid tumors.
Braggio DA; Costas C de Faria F; Koller D; Jin F; Zewdu A; Lopez G; Batte K; Casadei L; Welliver M; Horrigan SK; Han R; Larson JL; Strohecker AM; Pollock RE
PLoS One; 2022; 17(10):e0276047. PubMed ID: 36240209
[TBL] [Abstract] [Full Text] [Related]
7. Congenital Teratocarcinosarcoma With
Almarzooqi S; Reyes-Múgica M; Ali BR; Habbal A; Asha MJ; AlShamsi ET
Pediatr Dev Pathol; 2022; 25(5):562-567. PubMed ID: 35732187
[TBL] [Abstract] [Full Text] [Related]
8. Systemic Chemotherapies Retain Antitumor Activity in Desmoid Tumors Independent of Specific Mutations in ctnnb1 or APC: A Multi-institutional Retrospective Study.
Nathenson MJ; Hu J; Ratan R; Somaiah N; Hsu R; DeMaria PJ; Catoe HW; Pang A; Subhawong TK; Amini B; Sweet K; Feister K; Malik K; Jagannathan J; Braschi-Amirfarzan M; Sheren J; Caldas Y; Moreno Tellez C; Rosenberg AE; Lazar AJ; Maki RG; Benedetto P; Cohen J; Trent JC; Ravi V; Patel S; Wilky BA
Clin Cancer Res; 2022 Sep; 28(18):4092-4104. PubMed ID: 35180772
[TBL] [Abstract] [Full Text] [Related]
9. Trends in diagnostic and therapeutic strategies for extra-abdominal desmoid-type fibromatosis: Japanese musculoskeletal oncology group questionnaire survey.
Murase F; Nishida Y; Hamada S; Sakai T; Shimizu K; Ueda T
Jpn J Clin Oncol; 2021 Nov; 51(11):1615-1621. PubMed ID: 34530455
[TBL] [Abstract] [Full Text] [Related]
10. bone marrow mesenchymal stromal cells in chronic myelomonocytic leukaemia: overactivated WNT/β-catenin signalling by parallel RNA sequencing and dysfunctional phenotypes.
Xu R; Huang X; Li C; Deng C; Li M; Wu P; Geng S; Lai P; Lu Z; Weng J; Du X
Br J Haematol; 2021 Jun; 193(5):928-940. PubMed ID: 33959953
[TBL] [Abstract] [Full Text] [Related]
11. Recurrent Wnt medulloblastoma treated with marrow-ablative chemotherapy and autologous hematopoietic progenitor cell rescue: a dual case report and review of the literature.
Harris MK; Shatara M; Funk Z; Stanek J; Boué DR; Jones J; Finlay JL; Abdelbaki MS
Childs Nerv Syst; 2022 Feb; 38(2):465-472. PubMed ID: 33948723
[TBL] [Abstract] [Full Text] [Related]
12. Outcomes by Clinical and Molecular Features in Children With Medulloblastoma Treated With Risk-Adapted Therapy: Results of an International Phase III Trial (SJMB03).
Gajjar A; Robinson GW; Smith KS; Lin T; Merchant TE; Chintagumpala M; Mahajan A; Su J; Bouffet E; Bartels U; Schechter T; Hassall T; Robertson T; Nicholls W; Gururangan S; Schroeder K; Sullivan M; Wheeler G; Hansford JR; Kellie SJ; McCowage G; Cohn R; Fisher MJ; Krasin MJ; Stewart CF; Broniscer A; Buchhalter I; Tatevossian RG; Orr BA; Neale G; Klimo P; Boop F; Srinivasan A; Pfister SM; Gilbertson RJ; Onar-Thomas A; Ellison DW; Northcott PA
J Clin Oncol; 2021 Mar; 39(7):822-835. PubMed ID: 33405951
[TBL] [Abstract] [Full Text] [Related]
13. Desmoid tumors: To treat or not to treat, That is the question.
Kasper B; Raut CP; Gronchi A
Cancer; 2020 Dec; 126(24):5213-5221. PubMed ID: 33022074
[TBL] [Abstract] [Full Text] [Related]
14. Risk factors of local recurrence after surgery in extraabdominal desmoid-type fibromatosis: A multicenter study in Japan.
Nishida Y; Hamada S; Kawai A; Kunisada T; Ogose A; Matsumoto Y; Ae K; Toguchida J; Ozaki T; Hirakawa A; Motoi T; Sakai T; Kobayashi E; Gokita T; Okamoto T; Matsunobu T; Shimizu K; Koike H
Cancer Sci; 2020 Aug; 111(8):2935-2942. PubMed ID: 32539220
[TBL] [Abstract] [Full Text] [Related]
15. PIK3CA somatic mutation in sinonasal teratocarcinosarcoma.
Belardinilli F; De Vincentiis L; D'Ecclesia A; Giannini G; Giangaspero F; Corsi A
Auris Nasus Larynx; 2021 Jun; 48(3):530-534. PubMed ID: 32389511
[TBL] [Abstract] [Full Text] [Related]
16. The management of desmoid tumours: A joint global consensus-based guideline approach for adult and paediatric patients.
Desmoid Tumor Working Group
Eur J Cancer; 2020 Mar; 127():96-107. PubMed ID: 32004793
[TBL] [Abstract] [Full Text] [Related]
17. Arotinoid trometamol inhibits arsenic trioxide-stimulated keratinocyte proliferation via the Wnt, Shh, and bone morphogenetic protein signaling pathways.
Zhou X; Yan L; Bu XL; Xu XG; Bi XL; Gu J
J Biol Regul Homeost Agents; 2019; 33(3):731-743. PubMed ID: 31232011
[TBL] [Abstract] [Full Text] [Related]
18. A lesion categorized between ghost cell odontogenic carcinoma and dentinogenic ghost cell tumor with ctnnb1 mutation.
Ohata Y; Kayamori K; Yukimori A; Sumikura K; Ohsako T; Harada H; Sakamoto K; Ikeda T
Pathol Int; 2018 May; 68(5):307-312. PubMed ID: 29575443
[TBL] [Abstract] [Full Text] [Related]
19. Comprehensive molecular profiling of advanced/metastatic olfactory neuroblastomas.
Topcagic J; Feldman R; Ghazalpour A; Swensen J; Gatalica Z; Vranic S
PLoS One; 2018; 13(1):e0191244. PubMed ID: 29324814
[TBL] [Abstract] [Full Text] [Related]
20. Molecular genetics and targeted therapy of WNT-related human diseases (Review).
Katoh M; Katoh M
Int J Mol Med; 2017 Sep; 40(3):587-606. PubMed ID: 28731148
[TBL] [Abstract] [Full Text] [Related]
[Next]
